{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:20:32Z","timestamp":1789395632641,"version":"build-2803163510"},"reference-count":57,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The treatment environment for chronic hepatitis C has undergone a revolution, particularly in genotype 1. Gone are interferon\u2010based therapy and its associated tolerability challenges, inadequate response rates and numerous baseline factors that affect response to therapy. New and emerging treatment regimens employ all\u2010oral combinations of direct\u2010acting antiviral agents, and results of clinical trials suggest that these regimens routinely achieve cure rates &gt;90%, even in patients who failed prior interferon\u2010based triple therapy. In 2015, three all\u2010oral <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>\u2010approved regiments will be available for genotype 1 (sofosbuvir \/ledipasvir, sofosbuvir\/simeprevir, and paritaprevir\/r\/ombitasvir\/dasabuvir). Furthermore, new treatment combinations appear to be more tolerable and require shorter duration of therapy. We provide an overview of the classes of direct\u2010acting antiviral agents (<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s), the clinical factors affecting their integration into combination therapies and recent findings from trials of such combination therapies in patients with genotype 1 <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection.<\/jats:p>","DOI":"10.1111\/jvh.12422","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T11:41:25Z","timestamp":1434541285000},"page":"861-870","source":"Crossref","is-referenced-by-count":70,"title":["Interferon\u2010free, direct\u2010acting antiviral therapy for chronic hepatitis C"],"prefix":"10.1111","volume":"22","author":[{"given":"J. A.","family":"Gutierrez","sequence":"first","affiliation":[{"name":"The Texas Liver Institute University of Texas Health Science Center San Antonio TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Lawitz","sequence":"additional","affiliation":[{"name":"The Texas Liver Institute University of Texas Health Science Center San Antonio TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Poordad","sequence":"additional","affiliation":[{"name":"The Texas Liver Institute University of Texas Health Science Center San Antonio TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02748.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.014"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.037"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23192"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.02.013"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042010-085715"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.030"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep04765"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.029"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401398x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20032"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12068"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/267483"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5386.103"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.009"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02713.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2011.10.030"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.07.022"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50218"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-012-0309-x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306227"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.009"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213557"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"e_1_2_8_31_1","article-title":"Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in\u00a0patients with decompensated cirrhosis: Preliminary results of a prospective, multicenter study","author":"Flamm S","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-011-0101-7"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000101738.27552.9D"},{"issue":"1","key":"e_1_2_8_34_1","first-page":"O10","article-title":"Safety and efficacy of the all\u2010oral regimen of MK\u20105173\/MK\u20108742\u00a0\u00b1\u00a0ribavirin in treatment\u2010naive, non\u2010cirrhotic patients with hepatitis C virus genotype 1 infection: the C\u2010WORTHY study","volume":"60","author":"Hezode C","year":"2014","journal-title":"J Hepatol"},{"key":"e_1_2_8_35_1","unstructured":"KohliA SimsZ MartiMet\u00a0al.Combination oral hepatitis C antiviral therapy for 6 or 12\u00a0weeks: Final results of the SYNERGY trial.21st Conference on Retroviruses and Opportunistic Infections2014: Abstract 27LB."},{"key":"e_1_2_8_36_1","article-title":"C\u2010SWIFT: Grazoprevir (MK\u20105172) + elbasvir (MK\u20108742) + sofosbuvir in treatment\u2010naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8\u00a0weeks (interim results)","author":"Lawitz E","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)61466-5"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.057"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208809"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"issue":"1","key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(14)60060-X","article-title":"Results from the phase 2 pearl\u20101 study: interferon\u2010free regimens of abt\u2010450\/r\u00a0+\u00a0abt\u2010267 with or without ribavirin in patients with HCV genotype 4 infection","volume":"60","author":"Hezode C","journal-title":"J Hepatol"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19500"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2733"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.10.019"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)61467-7"},{"key":"e_1_2_8_54_1","article-title":"All\u2010oral, fixed\u2010dose combination therapy with daclatasvir\/asunaprevir\/BMS\u2010791325 for non\u2010cirrhotic patients with chronic HCV genotype 1 infection: UNITY\u20101 phase 3 SVR12 results","author":"Poordad F","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_55_1","article-title":"All\u2010oral fixed dose combination therapy with daclatasvir\/asunaprevir\/beclabuvir, +\/\u2010 ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY\u20102 phase 3 SVR12 results","author":"Muir A","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_56_1","unstructured":"Recommendations for testing managing and treating hepatitis C.American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA).2014."},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12422","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:46:30Z","timestamp":1696261590000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/jvh.12422"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12422","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]}}}